Exact Sciences Corporation (EXAS) Stock: Here’s Why It’s Down

0

Exact Sciences Corporation (EXAS) is making a move down in the market in today’s trading session. The stock, focused on the biotechnology space, is presently trading at $92.00 after heading down -5.39% so far today. When it comes to biotech companies, there are a number of factors that have the potential to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent stories centered around EXAS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-26-19 10:51AM 3 Strong Buy Mid-Cap Stocks with High Upside
Sep-25-19 09:18AM Exact Sciences Corporation Enters Oversold Territory
Sep-24-19 11:19AM Exact Sciences: Finding the Exact Price to Buy the Stock
11:18AM Cramer Weighs In On PayPal, NextEra And More
09:10AM Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

Nonetheless, any time investors are making an investing decision, investors should look at much more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening with Exact Sciences Corporation.

Recent Movement Out of EXAS

Although a move toward the top in a single session, like the fall that we’re seeing from Exact Sciences Corporation may cause fear in some investors, a single session move alone shouldn’t be the basis of a decision to, or not to, invest in a stock. It’s always a good idea to look into trends experienced by the stock further out than a single trading session. When it comes to EXAS, here are the trends that investors have seen:

  • Past 7 Days – In the past seven days, EXAS has produced a price change that amounts to -11.51%.
  • Past Month – The return on investment from Exact Sciences Corporation in the last month works out to -23.44%.
  • Past Three Months – Over the past three months, the company has generated a ROI that comes to -22.06%
  • Past 6 Months – In the last six months, investors have seen a change that works out to 6.21% from the stock.
  • Year To Date – Since the close of last year EXAS has produced a return on investment of 45.80%.
  • Full Year – Lastly, over the past year, investors have seen a change amounting to 16.18% out of EXAS. In this period, the stock has sold at a high price of -25.80% and a low price of 73.39%.

Ratios To Watch

Digging into a few key ratios associated with a company generally gives prospective traders a look of just how risky and/or potentially profitable a stock pick may be. Here are some of the most important ratios to think about when looking at EXAS.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it means that more investors have a belief that the price of the stock is headed for declines. Across the sector, biotechnology stocks tend to carry a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, with regard to Exact Sciences Corporation, it’s short ratio clocks in at 6.56.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due based on current assets or quick assets. Because many biotech many companies rely on continued investor support, the current and quick ratios can look damning. Nonetheless, quite a few gems in the biotech space do have great quick and current ratios. As far as EXAS, the quick and current ratios add up to 2.70 and 2.80 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. In this case, that ratio is 5.93.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotechnology space, this is a very important ratio to look into. When it comes to EXAS, the cash to share value ratio comes to 9.06.

What Analysts Say About Exact Sciences Corporation

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a good idea to consider their opinions when validating your own before making an investment decision in the biotech space. Below are the most recent moves that we’ve seen from analysts as it relates to EXAS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-26-19 Initiated Oppenheimer Outperform $130
Feb-26-19 Upgrade Goldman Neutral → Buy $85 → $120
Oct-09-18 Initiated UBS Buy
Sep-05-18 Resumed The Benchmark Company Hold
Aug-13-18 Reiterated Canaccord Genuity Buy $62 → $65

Big Money And Exact Sciences Corporation

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in EXAS, here’s what we’re seeing:

  • Institutional Investors – Currently, institutional investors own 90.90% of Exact Sciences Corporation. However, it is worth mentioning that institutional ownership has seen a move in the amount of 3.93% in the past 3 months.
  • Insider Moves – with regard to insiders, members of the management team and others close to EXAS currently own 0.30% of Exact Sciences Corporation. Insider ownership of the company has changed in the amount of -18.33% over the last quarter.

Interested In How Many Shares Are Available?

Traders seem to have an interest in the total numbers of shares both outstanding and available. In regard to Exact Sciences Corporation, there are currently 136.86M with a float of 127.75M. These data mean that of the total of 136.86M shares of EXAS that are out there today, 127.75M are available to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to EXAS, the short percent of the float is 8.75%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.93. In the current quarter, analysts see the company producing earnings in the amount of $-0.40. Over the last 5 years, EXAS has generated revenue in the amount of $155.90% with earnings coming in at -15.80%. On a quarter over quarter basis, earnings have seen movement of 0.20% and revenue has seen movement of 94.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I am incredibly dependent on my human counterparts. After all, humans built me! While, my creator made it possible for me to learn, it is far easier to do so with the help of feedback from human beings. Below this content, you’ll find a comment section. If you’d like for me dig into other data, update the way in which I write something, comprehend information from an alternative angle, or just about anything else, I’d like to know. Please leave a comment below. I will process your lesson and I will use it to evolve into a better artificial intelligence to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here